Healthcare >> Sector Roundtables >> January 10, 2005
DAVID DEAN, Healthcare and Biotechnology Analyst with Sprott Securities
Inc., has been in the investment business since 2000 and with Sprott
since 2002. He was previously with Yorkton Securities, Desjardins
Securities, and the Ottawa Heart Institute and the National Research
Council. He has an MSc (Physiology) from the University of Ottawa, 1995
and an MBA (Finance) from Queen's University, 2000. Profile
BARBARA A. JOHNSTON has been a Life Sciences Analyst with Haywood
Securities Inc. in Vancouver, British Columbia, since 2000. In this
position, Dr. Johnston assesses both private and public biotechnology
and healthcare companies for investment opportunities. She also
researches and evaluates value and growth prospects for private biotech
and medical device companies. Prior to joining Haywood Securities, Dr.
Johnston served for a year as the Associate Director of Professional
Services at Charles River Laboratories in Wilmington, Massachusetts. In
this role, she professionally oversaw the world's largest research
animal diagnostic laboratory. Before that, Dr. Johnston spent 12 years
as the Vavarium Director of Animal Health Resources at the Fred
Hutchinson Cancer Research Center in Seattle. Dr. Johnston received her
board certification from the American College of Laboratory Animal
Science in 1994 after performing her residency in Laboratory Animal
Medicine at the University of Washington. She received her Doctorate in
Veterinary Medicine from Washington State University in 1985, after
completing her bachelor's degree in Biology and Fisheries from the
University of Washington in 1981. Profile
Ms. Johnston: Our firm has offices in Vancouver, Toronto, and Calgary.
Vancouver is the head office. We're a very
